A Phase II, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Clinical Validity and Safety of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs Iron oxide-PEG (Primary)
- Indications Liver cancer
- Focus Diagnostic use
- Sponsors Megapro Biomedical Company
- 14 May 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 14 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2019.
- 20 Nov 2018 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.